Landscape → Oncology

CLL Clinical Trial Landscape

Data updated: May 20, 2026

767 clinical trials tracked since 2008

Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow, progressing slowly and typically affecting older adults. Clinical research into CLL remains active, with 764 trials registered since 2008. Currently, 257 trials are actively recruiting, enrolling, or continuing without recruitment. The majority of active trials are in early to mid-stage development, with 105 active Phase 1 trials out of 356 total, and 147 active Phase 2 trials out of 432 total. Phase 3 trials account for 39 active trials out of 81 total, while Phase 4 trials are less common, with only 4 active trials out of 8 total. Industry sponsorship is led by BeOne Medicines, which currently has 9 active trials. Acerta Pharma BV follows with 8 active trials, with AbbVie and Ascentage Pharma Group Inc. each sponsoring 7 active trials, and AstraZeneca sponsoring 5.

258 active

767 total (since 2008)

105

Phase 1 Active

356 total

147

Phase 2 Active

434 total

Phase 3 Active

82 total

Phase 4 Active

8 total

Top Industry Sponsors

Sorted by active Active Done Failed

BeOne Medicines 9 0 0

Acerta Pharma BV 8 3 0

AbbVie 7 10 1

Ascentage Pharma Group Inc. 7 0 0

AstraZeneca 5 5 2

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT04269902 RECRUITING

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

National Cancer Institute (NCI) n=247

NCT03844048 ACTIVE NOT RECRUITING

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

AbbVie n=165

NCT03701282 ACTIVE NOT RECRUITING

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

National Cancer Institute (NCI) n=720

NCT07582432 RECRUITING

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

Grifols Biologicals, LLC n=49

NCT06136559 RECRUITING

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Merck Sharp & Dohme LLC n=1,200

+ 77 more Phase 3 trials — see full database below

CLL — Trials Started by Year (last 10 years)

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

BeOne Medicines

Acerta Pharma BV

AbbVie

Ascentage Pharma Group Inc.

AstraZeneca

Loxo Oncology, Inc.

Nurix Therapeutics, Inc.

BeiGene

Merck

Newave Pharmaceutical Inc

Active Trials by Phase

Phase 1

105

Phase 2

147

Phase 3

Phase 4

Enrollment Size Distribution

1-50

415

51-200

223

201-500

501-1k

1k+

All Industry Sponsors

Sorted by active Active Done Failed

BeOne Medicines 9 0 0

Acerta Pharma BV 8 3 0

AbbVie 7 10 1

Ascentage Pharma Group Inc. 7 0 0

AstraZeneca 5 5 2

Loxo Oncology, Inc. 5 1 0

Nurix Therapeutics, Inc. 5 0 0

BeiGene 4 4 0

Merck 4 2 0

Newave Pharmaceutical Inc 3 0 0

Eli Lilly 3 0 0

Roche 2 10 1

Dizal (Jiangsu) Pharmaceutical Co., Ltd. 2 0 0

Novartis 1 3 3

Johnson & Johnson 1 4 0

NCT04269902 RECRUITING

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

National Cancer Institute (NCI) n=247

NCT03844048 ACTIVE NOT RECRUITING

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

AbbVie n=165

NCT03701282 ACTIVE NOT RECRUITING

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

National Cancer Institute (NCI) n=720

NCT07582432 RECRUITING

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

Grifols Biologicals, LLC n=49

NCT06136559 RECRUITING

Merck Sharp & Dohme LLC n=1,200

NCT02970318 ACTIVE NOT RECRUITING

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Acerta Pharma BV n=310

NCT06943872 RECRUITING

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

BeOne Medicines n=630

NCT06846671 RECRUITING

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

BeOne Medicines n=250

NCT07277231 RECRUITING

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

BeOne Medicines n=500

NCT06970743 RECRUITING

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

BeOne Medicines n=150

NCT06973187 RECRUITING

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

BeOne Medicines n=500

NCT05947851 RECRUITING

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

Merck Sharp & Dohme LLC n=735

NCT06073821 ACTIVE NOT RECRUITING

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

BeOne Medicines n=652

NCT01804686 RECRUITING

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Janssen Research & Development, LLC n=700

NCT01886872 ACTIVE NOT RECRUITING

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

National Cancer Institute (NCI) n=547

NCT03737981 ACTIVE NOT RECRUITING

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

National Cancer Institute (NCI) n=465

NCT02048813 ACTIVE NOT RECRUITING

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI) n=529

NCT07342478 RECRUITING

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Newave Pharmaceutical Inc n=306

NCT04666038 ACTIVE NOT RECRUITING

Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Loxo Oncology, Inc. n=238

NCT05254743 RECRUITING

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Loxo Oncology, Inc. n=662

NCT05645107 RECRUITING

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Grifols Therapeutics LLC n=386

NCT06428019 RECRUITING

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

AbbVie n=170

NCT07516093 NOT YET RECRUITING

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Nurix Therapeutics, Inc. n=620

NCT07139873 RECRUITING

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

Dizal (Jiangsu) Pharmaceutical Co., Ltd. n=250

NCT02477696 ACTIVE NOT RECRUITING

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

Acerta Pharma BV n=533

NCT05624554 ACTIVE NOT RECRUITING

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Merck Sharp & Dohme LLC n=300

NCT03336333 ACTIVE NOT RECRUITING

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

BeiGene n=590

NCT04075292 ACTIVE NOT RECRUITING

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

AstraZeneca n=155

NCT03480360 ACTIVE NOT RECRUITING

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Dartmouth-Hitchcock Medical Center n=21

NCT05057494 ACTIVE NOT RECRUITING

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

AstraZeneca n=607

NCT04965493 ACTIVE NOT RECRUITING

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Loxo Oncology, Inc. n=600

NCT05023980 ACTIVE NOT RECRUITING

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Loxo Oncology, Inc. n=309

NCT07321652 NOT YET RECRUITING

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Alliance for Clinical Trials in Oncology n=466

NCT05556720 ACTIVE NOT RECRUITING

Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

Monash University n=960

NCT06104566 RECRUITING

Global Trial in APG2575 for Patients With CLL/SLL

Ascentage Pharma Group Inc. n=400

NCT02475681 ACTIVE NOT RECRUITING

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

Acerta Pharma BV n=535

NCT05197192 RECRUITING

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

German CLL Study Group n=202

NCT03836261 ACTIVE NOT RECRUITING

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Acerta Pharma BV n=984

NCT06319456 RECRUITING

A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

Ascentage Pharma Group Inc. n=344

NCT03868722 RECRUITING

Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment

Rigshospitalet, Denmark n=212

NCT01231412 COMPLETED

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Fred Hutchinson Cancer Center n=174

NCT04285567 COMPLETED

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Hoffmann-La Roche n=166

NCT04008706 COMPLETED

Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

AstraZeneca n=552

NCT04502030 COMPLETED

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Octapharma n=247

NCT03734016 COMPLETED

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

BeiGene n=652

NCT04178798 COMPLETED

Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia

PETHEMA Foundation n=22

NCT00769522 COMPLETED

FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia

German CLL Study Group n=564

NCT02950051 COMPLETED

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

German CLL Study Group n=926

NCT02863718 COMPLETED

Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression

German CLL Study Group n=515

NCT02612311 TERMINATED

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

TG Therapeutics, Inc. n=603

NCT01724346 COMPLETED

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Pharmacyclics LLC. n=269

NCT03406156 COMPLETED

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

AbbVie n=120

NCT03801525 TERMINATED

Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)

TG Therapeutics, Inc. n=277

NCT02005471 COMPLETED

A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Hoffmann-La Roche n=389

NCT02049515 COMPLETED

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07

SecuraBio n=99

NCT02004522 COMPLETED

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

SecuraBio n=319

NCT01951885 COMPLETED

Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention

Case Comprehensive Cancer Center n=101

NCT02756611 COMPLETED

A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

AbbVie n=258

NCT02980731 COMPLETED

A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).

AbbVie n=210

NCT02301156 COMPLETED

Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)

TG Therapeutics, Inc. n=126

NCT01556776 COMPLETED

A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy

German CLL Study Group n=89

NCT00774345 COMPLETED

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

Celgene n=317

NCT02264574 COMPLETED

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Pharmacyclics LLC. n=229

NCT01569295 COMPLETED

Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )

Gilead Sciences n=416

NCT01611090 COMPLETED

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Janssen Research & Development, LLC n=578

NCT02801578 COMPLETED

A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)

M.D. Anderson Cancer Center n=11

NCT01118234 COMPLETED

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Arbeitsgemeinschaft medikamentoese Tumortherapie n=256

NCT01578707 COMPLETED

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Pharmacyclics LLC. n=391

NCT01905943 COMPLETED

A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia

Hoffmann-La Roche n=979

NCT01539291 TERMINATED

Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)

Gilead Sciences n=161

NCT01659021 TERMINATED

Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Gilead Sciences n=261

NCT00910910 COMPLETED

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

Celgene n=450

NCT01539512 COMPLETED

A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Gilead Sciences n=220

NCT01980888 TERMINATED

Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Gilead Sciences n=311

NCT01980875 TERMINATED

Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Gilead Sciences n=57

NCT01973387 COMPLETED

A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma

Janssen Research & Development, LLC n=160

NCT01722487 COMPLETED

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

Pharmacyclics LLC. n=269

NCT01500083 COMPLETED

Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia

Lundbeck Canada Inc. n=90

NCT00714259 TERMINATED

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

University of Alabama at Birmingham n=5

NCT01580228 COMPLETED

A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)

Merck Sharp & Dohme LLC n=44

NCT01892618 COMPLETED

Pneumococcal Vaccine in Untreated CLL Patients

Karolinska University Hospital n=134

NCT00799461 COMPLETED

Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium n=1,337

NCT07259070 RECRUITING

Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma

Institute of Hematology & Blood Diseases Hospital, China

NCT07061951 RECRUITING

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

NCT06588478 RECRUITING

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Loxo Oncology, Inc.

NCT07582159 NOT YET RECRUITING

Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

City of Hope Medical Center

NCT05006716 RECRUITING

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

BeOne Medicines

NCT02506933 ACTIVE NOT RECRUITING

Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant

City of Hope Medical Center

NCT05672251 RECRUITING

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

City of Hope Medical Center

NCT05718869 ACTIVE NOT RECRUITING

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

City of Hope Medical Center

NCT03824483 RECRUITING

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Memorial Sloan Kettering Cancer Center

NCT04657094 ACTIVE NOT RECRUITING

Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

City of Hope Medical Center

NCT04623541 ACTIVE NOT RECRUITING

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Genmab

NCT02029443 ACTIVE NOT RECRUITING

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Acerta Pharma BV

NCT06364423 RECRUITING

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

National Cancer Institute (NCI)

NCT07194980 RECRUITING

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Fred Hutchinson Cancer Center

NCT07557056 NOT YET RECRUITING

Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Jennifer Woyach

NCT01500733 ACTIVE NOT RECRUITING

PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Heart, Lung, and Blood Institute (NHLBI)

NCT06839053 RECRUITING

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Fred Hutchinson Cancer Center

NCT06637501 ACTIVE NOT RECRUITING

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

BeOne Medicines

NCT03932331 ACTIVE NOT RECRUITING

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

AstraZeneca

NCT03960840 ACTIVE NOT RECRUITING

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Novartis Pharmaceuticals

NCT05294731 RECRUITING

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

BeiGene

NCT02131584 ACTIVE NOT RECRUITING

Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center

NCT07221500 RECRUITING

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Nurix Therapeutics, Inc.

NCT02514083 ACTIVE NOT RECRUITING

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

National Heart, Lung, and Blood Institute (NHLBI)

NCT04169737 RECRUITING

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

M.D. Anderson Cancer Center

NCT01589302 ACTIVE NOT RECRUITING

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

Kami Maddocks, MD

NCT07520006 NOT YET RECRUITING

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Nurix Therapeutics, Inc.

NCT04560322 RECRUITING

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Massachusetts General Hospital

NCT07526597 NOT YET RECRUITING

Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors

UNC Lineberger Comprehensive Cancer Center

NCT05183854 RECRUITING

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

University of Utah

NCT04722172 ACTIVE NOT RECRUITING

A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

Memorial Sloan Kettering Cancer Center

NCT03467867 ACTIVE NOT RECRUITING

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

Georgetown University

NCT07508995 NOT YET RECRUITING

A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

M.D. Anderson Cancer Center

NCT06533579 RECRUITING

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Vironexis Biotherapeutics Inc.

NCT07271667 RECRUITING

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Curis, Inc.

NCT05702853 RECRUITING

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

Medical University of South Carolina

NCT05147467 RECRUITING

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Ascentage Pharma Group Inc.

NCT02717611 ACTIVE NOT RECRUITING

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Acerta Pharma BV

NCT05388006 RECRUITING

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Mayo Clinic

NCT06863402 RECRUITING

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Roswell Park Cancer Institute

NCT03534323 ACTIVE NOT RECRUITING

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

Dana-Farber Cancer Institute

NCT04458610 ACTIVE NOT RECRUITING

Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

M.D. Anderson Cancer Center

NCT02952508 ACTIVE NOT RECRUITING

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

Cellectar Biosciences, Inc.

NCT04904588 ACTIVE NOT RECRUITING

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

Center for International Blood and Marrow Transplant Research

NCT05478512 ACTIVE NOT RECRUITING

Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL

Gruppo Italiano Malattie EMatologiche dell'Adulto

NCT06859424 RECRUITING

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Center for International Blood and Marrow Transplant Research

NCT07459608 NOT YET RECRUITING

Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma

Henan Cancer Hospital

NCT07218510 RECRUITING

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

City of Hope Medical Center

NCT05458297 ACTIVE NOT RECRUITING

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Merck Sharp & Dohme LLC

NCT06059391 RECRUITING

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

City of Hope Medical Center

NCT02629809 ACTIVE NOT RECRUITING

Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center

NCT02339922 ACTIVE NOT RECRUITING

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

University of Washington

NCT05479994 ACTIVE NOT RECRUITING

Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

BeiGene

NCT04416984 ACTIVE NOT RECRUITING

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Allogene Therapeutics

NCT05873712 RECRUITING

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

Aseel Alsouqi

NCT04195633 RECRUITING

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Fred Hutchinson Cancer Center

NCT04624633 ACTIVE NOT RECRUITING

Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

Jennifer R. Brown, MD, PhD

NCT06524375 ACTIVE NOT RECRUITING

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period

Genentech, Inc.

NCT03986034 RECRUITING

Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

National Heart, Lung, and Blood Institute (NHLBI)

NCT05589896 RECRUITING

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Ossium Health, Inc.

NCT04186520 RECRUITING

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Medical College of Wisconsin

NCT05336812 RECRUITING

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center

NCT02756897 ACTIVE NOT RECRUITING

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

M.D. Anderson Cancer Center

NCT06466122 RECRUITING

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

Kerry Rogers

NCT02846623 ACTIVE NOT RECRUITING

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

M.D. Anderson Cancer Center

NCT03580928 ACTIVE NOT RECRUITING

Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL

Dana-Farber Cancer Institute

NCT02158091 ACTIVE NOT RECRUITING

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

Dana-Farber Cancer Institute

NCT05677919 ACTIVE NOT RECRUITING

Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia

Mayo Clinic

NCT06644183 RECRUITING

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Jennifer R. Brown, MD, PhD

NCT03516617 RECRUITING

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Mayo Clinic

NCT04895436 RECRUITING

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

AbbVie

NCT03513562 ACTIVE NOT RECRUITING

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

Ohio State University Comprehensive Cancer Center

NCT06001385 ACTIVE NOT RECRUITING

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

Center for International Blood and Marrow Transplant Research

NCT04419519 ACTIVE NOT RECRUITING

Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

Memorial Sloan Kettering Cancer Center

NCT02427451 ACTIVE NOT RECRUITING

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

Kerry Rogers

NCT06333262 RECRUITING

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

Inhye Ahn

NCT07024706 NOT YET RECRUITING

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

AstraZeneca

NCT05417165 RECRUITING

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

Seema Bhat

NCT06043674 RECRUITING

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Christine Ryan

NCT07108998 RECRUITING

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

Zulfa Omer

NCT07014917 RECRUITING

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

Zulfa Omer

NCT04523428 RECRUITING

REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

Stichting Hemato-Oncologie voor Volwassenen Nederland

NCT03277729 ACTIVE NOT RECRUITING

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Fred Hutchinson Cancer Center

NCT03961672 ACTIVE NOT RECRUITING

Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

City of Hope Medical Center

NCT04505254 RECRUITING

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center

NCT07154264 RECRUITING

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

NCT02966756 RECRUITING

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

AbbVie

NCT03622788 ACTIVE NOT RECRUITING

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

M.D. Anderson Cancer Center

NCT06697184 ACTIVE NOT RECRUITING

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

BeiGene

NCT06757647 RECRUITING

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Seema Bhat

NCT07052695 RECRUITING

Mosunetuzumab for CLL MRD Clearance

Inhye Ahn

NCT05672173 RECRUITING

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

City of Hope Medical Center

NCT05168930 RECRUITING

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

Dana-Farber Cancer Institute

NCT04963946 ACTIVE NOT RECRUITING

STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia

French Innovative Leukemia Organisation

NCT04844528 RECRUITING

Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers

University of Utah

NCT06539182 RECRUITING

DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

Dizal Pharmaceuticals

NCT03734198 ACTIVE NOT RECRUITING

Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

French Innovative Leukemia Organisation

NCT06958705 RECRUITING

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

The First Affiliated Hospital with Nanjing Medical University

NCT03128879 RECRUITING

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

M.D. Anderson Cancer Center

NCT01351896 ACTIVE NOT RECRUITING

Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

NCT04941716 RECRUITING

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

Fred Hutchinson Cancer Center

NCT04060277 ACTIVE NOT RECRUITING

Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

City of Hope Medical Center

NCT05643742 RECRUITING

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

CRISPR Therapeutics AG

NCT02007044 ACTIVE NOT RECRUITING

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center

NCT06967610 RECRUITING

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

M.D. Anderson Cancer Center

NCT05031897 RECRUITING

Two Step Haplo With Radiation Conditioning

Thomas Jefferson University

NCT02251548 ACTIVE NOT RECRUITING

A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia

Dana-Farber Cancer Institute

NCT04447768 ACTIVE NOT RECRUITING

The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

Memorial Sloan Kettering Cancer Center

NCT06520098 RECRUITING

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

VA Office of Research and Development

NCT04679012 RECRUITING

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Weill Medical College of Cornell University

NCT06979076 NOT YET RECRUITING

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL

MingSight Pharmaceuticals, Inc

NCT05944978 ACTIVE NOT RECRUITING

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

Sichuan Baili Pharmaceutical Co., Ltd.

NCT06849713 RECRUITING

Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL

Massachusetts General Hospital

NCT03162536 ACTIVE NOT RECRUITING

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

NCT04501939 ACTIVE NOT RECRUITING

Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax

University of California, San Diego

NCT03765177 RECRUITING

CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies

Ottawa Hospital Research Institute

NCT06978088 RECRUITING

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

Zulfa Omer

NCT06812715 RECRUITING

Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib

Peter MacCallum Cancer Centre, Australia

NCT05805605 RECRUITING

Allo HSCT Using RIC and PTCy for Hematological Diseases

Masonic Cancer Center, University of Minnesota

NCT03314974 RECRUITING

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Masonic Cancer Center, University of Minnesota

NCT06862323 NOT YET RECRUITING

Time Restricted Eating in Haematological Malignancies

British Columbia Cancer Agency

NCT07003464 NOT YET RECRUITING

Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study

The First Hospital of Jilin University

NCT01361711 ACTIVE NOT RECRUITING

Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Northwestern University

NCT05908409 RECRUITING

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

IDP Discovery Pharma S.L.

NCT04494503 RECRUITING

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Ascentage Pharma Group Inc.

NCT05281809 RECRUITING

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

John Lister

NCT06762431 ENROLLING BY INVITATION

Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.

Vitebsk Regional Clinical Cancer Centre

NCT03153202 ACTIVE NOT RECRUITING

Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

Joshua Brody

NCT06544785 RECRUITING

Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PETHEMA Foundation

NCT06506643 RECRUITING

Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms

Vector Vitale LLC

NCT03676504 RECRUITING

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

University Hospital Heidelberg

NCT06476899 NOT YET RECRUITING

A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy

Fei Li

NCT04082897 ACTIVE NOT RECRUITING

ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Niguarda Hospital

NCT05869279 RECRUITING

Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia

Fondazione Matilde Tettamanti Menotti De Marchi Onlus

NCT06367374 NOT YET RECRUITING

MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL

Institute of Hematology & Blood Diseases Hospital, China

NCT05791409 RECRUITING

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

Stichting Hemato-Oncologie voor Volwassenen Nederland

NCT05694312 RECRUITING

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Gruppo Italiano Malattie EMatologiche dell'Adulto

NCT05959694 RECRUITING

A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NCT04758975 RECRUITING

Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)

Paolo Ghia

NCT04908228 RECRUITING

Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL

Paolo Ghia

NCT05918276 NOT YET RECRUITING

Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL

Nanfang Hospital, Southern Medical University

NCT04935684 RECRUITING

Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation

University Hospital, Clermont-Ferrand

NCT03226301 ACTIVE NOT RECRUITING

A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Stichting Hemato-Oncologie voor Volwassenen Nederland

NCT04639362 ACTIVE NOT RECRUITING

CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

Stichting Hemato-Oncologie voor Volwassenen Nederland

NCT04771507 RECRUITING

A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)

Jeanette Lundin

NCT03980002 RECRUITING

A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL

Institute of Hematology & Blood Diseases Hospital, China

NCT02362035 COMPLETED

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

Acerta Pharma BV

NCT04205409 COMPLETED

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

University of Washington

NCT02518555 COMPLETED

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Jennifer Woyach

NCT01723839 COMPLETED

Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide

Hackensack Meridian Health

NCT02135133 COMPLETED

A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL

Dana-Farber Cancer Institute

NCT02213913 COMPLETED

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

University of Chicago

NCT05672355 SUSPENDED

A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia

City of Hope Medical Center

NCT03514017 TERMINATED

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

H. Lee Moffitt Cancer Center and Research Institute

NCT03609593 COMPLETED

Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

Nicole Lamanna

NCT04282018 COMPLETED

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

BeiGene

NCT02649387 COMPLETED

Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy

Mayo Clinic

NCT04809467 TERMINATED

A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

Incyte Corporation

NCT03204188 COMPLETED

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

National Heart, Lung, and Blood Institute (NHLBI)

NCT04116437 COMPLETED

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

BeiGene

NCT03740529 COMPLETED

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Loxo Oncology, Inc.

NCT02337829 COMPLETED

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Acerta Pharma BV

NCT04163718 TERMINATED

TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)

H. Lee Moffitt Cancer Center and Research Institute

NCT03708003 TERMINATED

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

Swiss Cancer Institute

NCT04230304 TERMINATED

Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

Mayo Clinic

NCT01496976 COMPLETED

Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL

H. Lee Moffitt Cancer Center and Research Institute

NCT05317936 TERMINATED

Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax

M.D. Anderson Cancer Center

NCT02005289 COMPLETED

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Ohio State University Comprehensive Cancer Center

NCT04191187 COMPLETED

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

H. Lee Moffitt Cancer Center and Research Institute

NCT04010968 COMPLETED

Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia

French Innovative Leukemia Organisation

NCT01760655 COMPLETED

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT05105841 COMPLETED

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

AbbVie

NCT02315768 COMPLETED

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

University of California, San Diego

NCT01750567 COMPLETED

A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL

University of Michigan Rogel Cancer Center

NCT03207555 COMPLETED

Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

M.D. Anderson Cancer Center

NCT02793544 COMPLETED

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

Center for International Blood and Marrow Transplant Research

NCT03333486 TERMINATED

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Roswell Park Cancer Institute

NCT02722668 COMPLETED

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Masonic Cancer Center, University of Minnesota

NCT06839872 WITHDRAWN

A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

AstraZeneca

NCT03246906 TERMINATED

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Fred Hutchinson Cancer Center

NCT05405309 TERMINATED

RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia

University of Utah

NCT04189952 TERMINATED

Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

University of Miami

NCT04685915 WITHDRAWN

Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

Inhye Ahn

NCT01350245 COMPLETED

Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT01532635 TERMINATED

A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT03492125 TERMINATED

A Study Of The Selective PKC-β Inhibitor MS- 553

MingSight Pharmaceuticals, Inc

NCT03615105 TERMINATED

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Memorial Sloan Kettering Cancer Center

NCT04419389 TERMINATED

APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)

Aprea Therapeutics

NCT02396134 COMPLETED

Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

City of Hope Medical Center

NCT04312841 COMPLETED

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Ohio State University Comprehensive Cancer Center

NCT03088878 COMPLETED

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Oncternal Therapeutics, Inc

NCT04716075 COMPLETED

Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)

Polish Lymphoma Research Group

NCT04305444 TERMINATED

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Zhejiang DTRM Biopharma

NCT03997968 COMPLETED

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Cyteir Therapeutics, Inc.

NCT02910583 COMPLETED

Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

Pharmacyclics LLC.

NCT05269940 COMPLETED

A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies

Nanjing Zenshine Pharmaceuticals

NCT03206918 COMPLETED

Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

BeiGene

NCT04358458 TERMINATED

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Genmab

NCT03788291 COMPLETED

Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

University of Rochester

NCT01243190 COMPLETED

Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

M.D. Anderson Cancer Center

NCT01199575 COMPLETED

Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

University of California, San Diego

NCT05720052 TERMINATED

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

MingSight Pharmaceuticals, Inc

NCT03088709 TERMINATED

Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide

Loyola University

NCT02742090 TERMINATED

Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy

TG Therapeutics, Inc.

NCT02100423 COMPLETED

Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Paolo Caimi, MD

NCT05465876 WITHDRAWN

Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL

Sunnybrook Health Sciences Centre

NCT03056339 COMPLETED

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

M.D. Anderson Cancer Center

NCT02420912 COMPLETED

Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation

M.D. Anderson Cancer Center

NCT06247540 WITHDRAWN

Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Northwestern University

NCT03128359 COMPLETED

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

City of Hope Medical Center

NCT02332980 COMPLETED

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Mayo Clinic

NCT05028374 COMPLETED

COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies

Barbara Ann Karmanos Cancer Institute

NCT03734601 COMPLETED

Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation

Stanford University

NCT04808570 TERMINATED

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NCT01145209 COMPLETED

Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

National Heart, Lung, and Blood Institute (NHLBI)

NCT03572634 TERMINATED

Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL

Sumitomo Pharma America, Inc.

NCT02869633 COMPLETED

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

Vanderbilt-Ingram Cancer Center

NCT03096782 COMPLETED

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

M.D. Anderson Cancer Center

NCT02661035 COMPLETED

Allo HSCT Using RIC for Hematological Diseases

Masonic Cancer Center, University of Minnesota

NCT01696461 COMPLETED

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Center for International Blood and Marrow Transplant Research

NCT01044745 TERMINATED

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

University of Nebraska

NCT01465334 TERMINATED

Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL

Dana-Farber Cancer Institute

NCT02340780 COMPLETED

Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia

Canadian Cancer Trials Group

NCT04029038 WITHDRAWN

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

M.D. Anderson Cancer Center

NCT03010358 COMPLETED

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Alexey Danilov, MD

NCT03702231 COMPLETED

Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)

National Heart, Lung, and Blood Institute (NHLBI)

NCT01627054 COMPLETED

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia

NCIC Clinical Trials Group

NCT04016805 TERMINATED

Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

TG Therapeutics, Inc.

NCT01572662 COMPLETED

Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

M.D. Anderson Cancer Center

NCT01013961 TERMINATED

Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia

ECOG-ACRIN Cancer Research Group

NCT02656303 TERMINATED

A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304

TG Therapeutics, Inc.

NCT01747486 COMPLETED

Dose Optimization Trial of CD19 Redirected Autologous T Cells

University of Pennsylvania

NCT04149821 TERMINATED

Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

Weill Medical College of Cornell University

NCT02440685 TERMINATED

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

Asana BioSciences

NCT00602459 COMPLETED

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

NCT02581007 COMPLETED

Reduced Intensity Conditioning Transplant Using Haploidentical Donors

Northside Hospital, Inc.

NCT05365100 WITHDRAWN

A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL

BioNova Pharmaceuticals (Shanghai) LTD.

NCT01168921 COMPLETED

Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)

M.D. Anderson Cancer Center

NCT05209308 WITHDRAWN

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

MEI Pharma, Inc.

NCT03370185 WITHDRAWN

Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

SecuraBio

NCT01066663 COMPLETED

Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Dana-Farber Cancer Institute

NCT04030195 COMPLETED

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

Precision BioSciences, Inc.

NCT02593123 COMPLETED

Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis

Virginia Commonwealth University

NCT02141282 COMPLETED

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

AbbVie

NCT01647971 COMPLETED

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

TG Therapeutics, Inc.

NCT02556931 COMPLETED

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02013128 COMPLETED

Ublituximab + Ibrutinib in Select B-cell Malignancies

TG Therapeutics, Inc.

NCT04504708 TERMINATED

Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies

Hangzhou Zenshine Pharmaceuticals Co., Ltd.

NCT02225275 TERMINATED

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

M.D. Anderson Cancer Center

NCT04282174 WITHDRAWN

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

Baptist Health South Florida

NCT03379051 TERMINATED

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

TG Therapeutics, Inc.

NCT04665115 WITHDRAWN

Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Academic and Community Cancer Research United

NCT03207256 TERMINATED

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

TG Therapeutics, Inc.

NCT01241786 TERMINATED

Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL

Hackensack Meridian Health

NCT01982175 SUSPENDED

Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia

Shanghai Zhangjiang Biotechnology Limited Company

NCT01865617 COMPLETED

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

Fred Hutchinson Cancer Center

NCT01455051 COMPLETED

Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

Grupo Espanol de trasplantes hematopoyeticos y terapia celular

NCT04155840 TERMINATED

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

University of Washington

NCT01994382 COMPLETED

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Alexion Pharmaceuticals, Inc.

NCT04660045 WITHDRAWN

Early Intervention With Acalabrutinib in Patients With High Risk CLL

Weill Medical College of Cornell University

NCT04209621 TERMINATED

Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

National Heart, Lung, and Blood Institute (NHLBI)

NCT03939234 COMPLETED

Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.

Lars Møller Pedersen

NCT00792831 TERMINATED

Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia

Italfarmaco

NCT02968563 COMPLETED

Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Gilead Sciences

NCT01125176 COMPLETED

Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL

Weill Medical College of Cornell University

NCT03153514 TERMINATED

Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation

German CLL Study Group

NCT02983617 COMPLETED

Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

Gilead Sciences

NCT02639910 COMPLETED

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

MorphoSys AG

NCT01889186 COMPLETED

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

AbbVie

NCT03943342 WITHDRAWN

Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Kerry Rogers

NCT01665768 COMPLETED

Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01585688 TERMINATED

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

Gilead Sciences

NCT03045328 COMPLETED

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

Steven E. Coutre

NCT00759798 COMPLETED

Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)

M.D. Anderson Cancer Center

NCT00546793 COMPLETED

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

Gilead Sciences

NCT02265731 COMPLETED

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

AbbVie

NCT01444716 COMPLETED

Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center

NCT00792077 COMPLETED

A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue

M.D. Anderson Cancer Center

NCT02424968 COMPLETED

CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

Robert Lowsky

NCT01188681 COMPLETED

Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia

Aptevo Therapeutics

NCT01716208 COMPLETED

Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma

Joseph Tuscano

NCT01497496 COMPLETED

Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

H. Lee Moffitt Cancer Center and Research Institute

NCT03041636 COMPLETED

Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

M.D. Anderson Cancer Center

NCT01441882 COMPLETED

Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia

OHSU Knight Cancer Institute

NCT03076437 COMPLETED

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

Shenzhen Institute for Innovation and Translational Medicine

NCT03755947 COMPLETED

Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

Grupo Cooperativo de Hemopatías Malignas

NCT02309515 TERMINATED

Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis

Mayo Clinic

NCT01930162 COMPLETED

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant

Novartis Pharmaceuticals

NCT01474681 COMPLETED

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

Novartis Pharmaceuticals

NCT01799889 TERMINATED

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Gilead Sciences

NCT01258998 COMPLETED

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

National Cancer Institute (NCI)

NCT03037645 TERMINATED

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

Sunesis Pharmaceuticals

NCT02991898 TERMINATED

Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies

Masonic Cancer Center, University of Minnesota

NCT03097770 COMPLETED

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Chinese PLA General Hospital

NCT01885897 COMPLETED

IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT

Masonic Cancer Center, University of Minnesota

NCT01269385 COMPLETED

Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia

Mayo Clinic

NCT01003769 TERMINATED

Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia

Mayo Clinic

NCT02689141 COMPLETED

Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)

German CLL Study Group

NCT01796470 TERMINATED

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Gilead Sciences

NCT02481297 COMPLETED

Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

M.D. Anderson Cancer Center

NCT01109069 COMPLETED

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

Pharmacyclics LLC.

NCT00918333 COMPLETED

Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma

Mayo Clinic

NCT00918723 COMPLETED

Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Fred Hutchinson Cancer Center

NCT01629511 TERMINATED

Allogeneic Stem Cell Transplant for CLL

M.D. Anderson Cancer Center

NCT02320487 COMPLETED

A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Genentech, Inc.

NCT00632359 COMPLETED

Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease

M.D. Anderson Cancer Center

NCT02071225 COMPLETED

A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia

Hoffmann-La Roche

NCT00789776 COMPLETED

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

Fred Hutchinson Cancer Center

NCT00899431 TERMINATED

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

M.D. Anderson Cancer Center

NCT01527045 COMPLETED

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Fred Hutchinson Cancer Center

NCT01576588 COMPLETED

Rituximab in Pretreated Elderly or Unfit B-CLL Patients

Prof. Dr. Med. Laimonas Griskevicius

NCT00723099 COMPLETED

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Fred Hutchinson Cancer Center

NCT02557516 TERMINATED

Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL

Innate Pharma

NCT01326702 COMPLETED

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

National Cancer Institute (NCI)

NCT01251575 COMPLETED

Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Fred Hutchinson Cancer Center

NCT00974233 COMPLETED

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

University of Wisconsin, Madison

NCT01754870 WITHDRAWN

Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

University of Wisconsin, Madison

NCT02530515 COMPLETED

Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center

NCT01392079 COMPLETED

Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine

University of Ulm

NCT03195010 TERMINATED

Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia

Fred Hutchinson Cancer Center

NCT01529827 COMPLETED

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Roswell Park Cancer Institute

NCT01532700 COMPLETED

An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)

University Health Network, Toronto

NCT01090414 TERMINATED

An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study

Gilead Sciences

NCT00949988 TERMINATED

A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia

University of California, San Diego

NCT01839916 COMPLETED

Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

University of Chicago

NCT01159067 TERMINATED

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

City of Hope Medical Center

NCT01008462 COMPLETED

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Fred Hutchinson Cancer Center

NCT01002755 COMPLETED

Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

M.D. Anderson Cancer Center

NCT00711828 COMPLETED

Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma

Mayo Clinic

NCT00829647 WITHDRAWN

A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia

Scripps Health

NCT00648739 TERMINATED

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

Alexion Pharmaceuticals, Inc.

NCT01403246 TERMINATED

Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL)

Gruppo Italiano Malattie EMatologiche dell'Adulto

NCT01279252 COMPLETED

CLL Empirical Antibiotic Regimen

King's College Hospital NHS Trust

NCT01244451 COMPLETED

GIMEMA CLL0809 Study (BendOfa)

Gruppo Italiano Malattie EMatologiche dell'Adulto

NCT01408563 COMPLETED

Reduced Intensity Double Umbilical Cord Blood Transplantation

Massachusetts General Hospital

NCT02208037 COMPLETED

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

National Heart, Lung, and Blood Institute (NHLBI)

NCT00727415 COMPLETED

Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy

Gruppo Italiano Malattie EMatologiche dell'Adulto

NCT00860457 COMPLETED

Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)

Georgetown University

NCT03438344 WITHDRAWN

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

City of Hope Medical Center

NCT02044822 TERMINATED

Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

Gilead Sciences

NCT01203930 TERMINATED

A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL

Gilead Sciences

NCT00709592 COMPLETED

Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT

Virginia Commonwealth University

NCT00963105 COMPLETED

Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Celgene

NCT01024010 COMPLETED

Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Mayo Clinic

NCT00946023 TERMINATED

Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01789255 COMPLETED

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

National Cancer Institute (NCI)

NCT01610180 COMPLETED

Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

Fondazione Progetto Ematologia

NCT01517035 COMPLETED

Improving Blood Stem Cell Collection and Transplant Procedures

National Heart, Lung, and Blood Institute (NHLBI)

NCT01050764 TERMINATED

Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells

Everett Meyer

NCT01558167 COMPLETED

A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia

German CLL Study Group

NCT01191190 COMPLETED

Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)

Januario Castro, M.D.

NCT02877082 TERMINATED

Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients

Emory University

NCT01612988 TERMINATED

Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL

French Innovative Leukemia Organisation

NCT01030536 COMPLETED

Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)

MedImmune LLC

NCT01515176 COMPLETED

Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

National Cancer Institute (NCI)

NCT02371590 WITHDRAWN

Lenalidomide and Obinutuzumab for Previously Untreated CLL

University of California, San Diego

NCT01181258 COMPLETED

Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

Masonic Cancer Center, University of Minnesota

NCT02294552 COMPLETED

Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT

Ivan S Moiseev

NCT00867529 COMPLETED

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma

Fred Hutchinson Cancer Center

NCT00764517 COMPLETED

Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma

OHSU Knight Cancer Institute

NCT01163201 WITHDRAWN

T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies

Masonic Cancer Center, University of Minnesota

NCT02662296 WITHDRAWN

Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

NCT01369849 COMPLETED

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

NCT02677948 WITHDRAWN

Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

University of Michigan Rogel Cancer Center

NCT01419795 TERMINATED

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

NCT01848145 COMPLETED

Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia

SCRI Development Innovations, LLC

NCT01466153 COMPLETED

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

MedImmune LLC

NCT00795769 COMPLETED

Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

Fred Hutchinson Cancer Center

NCT01486797 COMPLETED

NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)

TME Pharma AG

NCT01011894 COMPLETED

Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age

Memorial Sloan Kettering Cancer Center

NCT01133743 COMPLETED

Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia

University Health Network, Toronto

NCT02371577 WITHDRAWN

Evaluation of the Immune Restoration Potential Of Lenalidomide

University of California, San Diego

NCT01868893 COMPLETED

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Genentech, Inc.

NCT01173679 TERMINATED

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

Massachusetts General Hospital

NCT02200380 TERMINATED

A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs

Celldex Therapeutics

NCT02285244 WITHDRAWN

Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation

James Blachly

NCT01944943 TERMINATED

Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia

The Lymphoma Academic Research Organisation

NCT01181271 COMPLETED

Tandem Auto-Allo Transplant for Lymphoma

Massachusetts General Hospital

NCT01744691 COMPLETED

A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Pharmacyclics LLC.

NCT01475058 COMPLETED

CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant

Fred Hutchinson Cancer Center

NCT02042911 COMPLETED

Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia

SymBio Pharmaceuticals

NCT01520922 COMPLETED

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Novartis Pharmaceuticals

NCT00536341 COMPLETED

Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

SCRI Development Innovations, LLC

NCT01681563 COMPLETED

Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Niguarda Hospital

NCT02086591 TERMINATED

A Phase II Study of Doxycycline in Relapsed NHL

University of Rochester

NCT01600053 TERMINATED

Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia

Thomas Kipps

NCT01459211 COMPLETED

Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL)

University College, London

NCT01087151 COMPLETED

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

Genentech, Inc.

NCT02015208 COMPLETED

Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia

Sunnybrook Health Sciences Centre

NCT01113632 COMPLETED

Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

SCRI Development Innovations, LLC

NCT00771056 TERMINATED

Hydroxychloroquine in Untreated B-CLL Patients

Northwell Health

NCT01652014 WITHDRAWN

Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies

University of Medicine and Dentistry of New Jersey

NCT02046928 TERMINATED

Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)

Ångstrom Pharmaceuticals

NCT01703364 COMPLETED

Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL

Arbeitsgemeinschaft medikamentoese Tumortherapie

NCT01370772 COMPLETED

Intensified Rituimab Prephase Before FCR in Untreated B-CLL

French Innovative Leukemia Organisation

NCT00975975 COMPLETED

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

Indiana University

NCT01413568 COMPLETED

Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies

Polyphor Ltd.

NCT01510756 TERMINATED

Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)

Thomas Kipps

NCT01419691 COMPLETED

Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)

University of Kansas Medical Center

NCT00942409 TERMINATED

Study of Repeat Intranodal Injections of Ad-ISF35

Januario Castro, M.D.

NCT00849524 TERMINATED

Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Januario Castro, M.D.

NCT01010568 TERMINATED

Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Georgetown University

NCT01123356 COMPLETED

Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab

Medical University of South Carolina

NCT02034227 TERMINATED

Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia

Spirogen

NCT00801060 TERMINATED

Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Biogen

NCT01625741 TERMINATED

Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

NCT00759603 COMPLETED

Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center

NCT01217749 COMPLETED

Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL

Pharmacyclics LLC.

NCT00771602 TERMINATED

Alemtuzumab + Rituximab Consolidation in CLL

M.D. Anderson Cancer Center

NCT01271283 WITHDRAWN

Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

NCT01397149 TERMINATED

Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)

University of Ulm

NCT00845104 WITHDRAWN

Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

NCT00916045 TERMINATED

Pilot Study of Unrelated Cord Blood Transplantation

King's College Hospital NHS Trust

NCT01310101 COMPLETED

Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia

Brno University Hospital

NCT01465230 TERMINATED

Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia

Yale University

NCT01557777 COMPLETED

Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)

AbbVie (prior sponsor, Abbott)

NCT01105247 COMPLETED

Safety of PCI-32765 in Chronic Lymphocytic Leukemia

Pharmacyclics LLC.

NCT00899353 TERMINATED

Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)

Marshall University

NCT01500161 TERMINATED

Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match

Texas Oncology Cancer Center

NCT01109264 COMPLETED

Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia

Jiangsu Simcere Pharmaceutical Co., Ltd.

NCT00873457 COMPLETED

Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Daphne Friedman

NCT01144260 COMPLETED

Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

CytRx

NCT01659047 WITHDRAWN

A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia

Gilead Sciences

NCT00962715 WITHDRAWN

Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center

NCT00640523 COMPLETED

Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)

BioCryst Pharmaceuticals

NCT00758693 WITHDRAWN

Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)

University of Kentucky

NCT01125787 TERMINATED

Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab

Nevada Cancer Institute

NCT00524667 TERMINATED

HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia

CancerCare Manitoba

NCT00918450 WITHDRAWN

Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen

Abbott

NCT00676871 WITHDRAWN

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)

MedImmune LLC

NCT02160015 ACTIVE NOT RECRUITING

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

NCT04771572 RECRUITING

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Newave Pharmaceutical Inc

NCT05618028 ACTIVE NOT RECRUITING

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

AbbVie

NCT05797233 ACTIVE NOT RECRUITING

Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

National Cancer Institute (NCI)

NCT05091424 RECRUITING

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Hoffmann-La Roche

NCT03913949 ACTIVE NOT RECRUITING

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Ascentage Pharma Group Inc.

NCT03479268 ACTIVE NOT RECRUITING

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

City of Hope Medical Center

NCT06859008 RECRUITING

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center

NCT05020678 ACTIVE NOT RECRUITING

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Nkarta, Inc.

NCT03328273 ACTIVE NOT RECRUITING

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Acerta Pharma BV

NCT03853616 ACTIVE NOT RECRUITING

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

Miltenyi Biomedicine GmbH

NCT07166419 RECRUITING

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center

NCT05131022 RECRUITING

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Nurix Therapeutics, Inc.

NCT03085173 ACTIVE NOT RECRUITING

A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

Memorial Sloan Kettering Cancer Center

NCT02537613 ACTIVE NOT RECRUITING

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Dana-Farber Cancer Institute

NCT07020533 RECRUITING

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

City of Hope Medical Center

NCT04830137 RECRUITING

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Nurix Therapeutics, Inc.

NCT04629729 ACTIVE NOT RECRUITING

FT819 in Subjects With B-cell Malignancies

Fate Therapeutics

NCT05828589 ACTIVE NOT RECRUITING

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

BeOne Medicines

NCT07424833 NOT YET RECRUITING

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

Ascentage Pharma Group Inc.

NCT04775745 RECRUITING

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Newave Pharmaceutical Inc

NCT06191887 RECRUITING

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Mayo Clinic

NCT05544019 RECRUITING

Study of SGR-1505 in Mature B-Cell Neoplasms

Schrödinger, Inc.

NCT00586391 ACTIVE NOT RECRUITING

CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL

Baylor College of Medicine

NCT03666000 RECRUITING

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Imugene Limited

NCT05512390 RECRUITING

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

AbbVie

NCT06528301 RECRUITING

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Umoja Biopharma

NCT06291220 ACTIVE NOT RECRUITING

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

AbbVie

NCT04843904 ACTIVE NOT RECRUITING

Safe Accelerated Venetoclax Escalation in CLL

Dana-Farber Cancer Institute

NCT03447808 ACTIVE NOT RECRUITING

Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Jennifer Woyach

NCT01853631 RECRUITING

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

Baylor College of Medicine

NCT03884998 ACTIVE NOT RECRUITING

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

City of Hope Medical Center

NCT05602363 RECRUITING

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Carna Biosciences, Inc.

NCT03560752 ACTIVE NOT RECRUITING

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

City of Hope Medical Center

NCT06708897 RECRUITING

A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas

Lomond Therapeutics Holdings, Inc.

NCT02050347 ACTIVE NOT RECRUITING

Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)

Baylor College of Medicine

NCT04684563 ACTIVE NOT RECRUITING

huCART19-IL18 in CD19+ Cancers

University of Pennsylvania

NCT06916767 RECRUITING

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Paolo Caimi, MD

NCT05943496 RECRUITING

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

OHSU Knight Cancer Institute

NCT07225439 NOT YET RECRUITING

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Paolo Caimi, MD

NCT04981912 ACTIVE NOT RECRUITING

Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients

University of California, San Diego

NCT06712810 RECRUITING

Q702 for the Treatment of Patients With Hematologic Malignancies

Mayo Clinic

NCT03198650 ACTIVE NOT RECRUITING

A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

AstraZeneca

NCT02153580 ACTIVE NOT RECRUITING

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

City of Hope Medical Center

NCT05878184 ACTIVE NOT RECRUITING

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Sana Biotechnology

NCT05971251 ACTIVE NOT RECRUITING

Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

University of Alabama at Birmingham

NCT05705570 RECRUITING

Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies

Nelson Hamerschlak

NCT06037018 RECRUITING

Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies

CytoCares Inc

NCT06735664 RECRUITING

Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation

City of Hope Medical Center

NCT07168486 ENROLLING BY INVITATION

CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

University of Maryland, Baltimore

NCT04007029 ACTIVE NOT RECRUITING

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Jonsson Comprehensive Cancer Center

NCT04464200 ACTIVE NOT RECRUITING

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

Memorial Sloan Kettering Cancer Center

NCT02157324 ACTIVE NOT RECRUITING

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

Acerta Pharma BV

NCT07108868 RECRUITING

A Phase I Dose Finding Study of MB-CART2219.1

University Hospital Tuebingen

NCT00840853 ACTIVE NOT RECRUITING

Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT

Baylor College of Medicine

NCT04732845 ACTIVE NOT RECRUITING

Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Benjamin Tomlinson

NCT05963217 RECRUITING

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

University Health Network, Toronto

NCT04892277 RECRUITING

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Mayo Clinic

NCT03774654 ACTIVE NOT RECRUITING

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

Baylor College of Medicine

NCT06547528 RECRUITING

A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

Ono Pharmaceutical Co., Ltd.

NCT05418088 RECRUITING

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Sumithira Vasu

NCT04215809 RECRUITING

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Ascentage Pharma Group Inc.

NCT05665062 ACTIVE NOT RECRUITING

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Synthekine

NCT04072458 ACTIVE NOT RECRUITING

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

Bio-Path Holdings, Inc.

NCT03283137 ACTIVE NOT RECRUITING

Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

University of Chicago

NCT04682808 ACTIVE NOT RECRUITING

A Study of FCN-338 in Patients With Chronic CLL/SLL

Fochon Pharmaceuticals, Ltd.

NCT06547944 ACTIVE NOT RECRUITING

Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Institute of Hematology & Blood Diseases Hospital, China

NCT03422393 ACTIVE NOT RECRUITING

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

Michael Choi

NCT04488354 COMPLETED

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Calibr, a division of Scripps Research

NCT02128945 COMPLETED

Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies

University Hospital, Caen

NCT03547115 TERMINATED

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

MEI Pharma, Inc.

NCT05694364 COMPLETED

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

H. Lee Moffitt Cancer Center and Research Institute

NCT00709033 COMPLETED

T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL

Baylor College of Medicine

NCT05665530 COMPLETED

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Prelude Therapeutics

NCT04155710 COMPLETED

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

Iovance Biotherapeutics, Inc.

NCT02296918 COMPLETED

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Acerta Pharma BV

NCT02860676 COMPLETED

Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961

University of California, San Diego

NCT05400122 SUSPENDED

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

David Wald

NCT02290951 COMPLETED

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

Regeneron Pharmaceuticals

NCT04240704 TERMINATED

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL

Novartis Pharmaceuticals

NCT04512105 COMPLETED

Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

University of California, Irvine

NCT04018248 COMPLETED

BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)

Boryung Pharmaceutical Co., Ltd

NCT04657224 COMPLETED

A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Janssen Research & Development, LLC

NCT06343376 TERMINATED

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Roswell Park Cancer Institute

NCT05153330 TERMINATED

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

Biomea Fusion Inc.

NCT01290302 COMPLETED

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

American Regent, Inc.

NCT02303392 COMPLETED

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Jennifer Woyach

NCT03400176 TERMINATED

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Novartis Pharmaceuticals

NCT01352312 TERMINATED

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT04578600 COMPLETED

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Joseph Tuscano

NCT04553692 TERMINATED

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

NCT03893682 TERMINATED

A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Aptose Biosciences Inc.

NCT04781855 WITHDRAWN

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

M.D. Anderson Cancer Center

NCT01638533 COMPLETED

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

National Cancer Institute (NCI)

NCT04887259 TERMINATED

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Lava Therapeutics

NCT04688385 COMPLETED

Personalized Multi-peptide Vaccination in CLL Patients

University Hospital Tuebingen

NCT02268851 COMPLETED

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

Dana-Farber Cancer Institute

NCT02924402 COMPLETED

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Xencor, Inc.

NCT03524235 COMPLETED

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Noah Merin

NCT03755154 TERMINATED

Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia

Institut de Recherches Internationales Servier

NCT03884829 TERMINATED

A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

Cyclacel Pharmaceuticals, Inc.

NCT05094206 TERMINATED

CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

Medical College of Wisconsin

NCT04450069 COMPLETED

CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

Calibr, a division of Scripps Research

NCT04806035 TERMINATED

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

TG Therapeutics, Inc.

NCT02920697 COMPLETED

Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma

Institut de Recherches Internationales Servier

NCT03671590 TERMINATED

Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

TG Therapeutics, Inc.

NCT03892044 COMPLETED

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

David Bond, MD

NCT01588015 COMPLETED

Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant

City of Hope Medical Center

NCT03151057 TERMINATED

Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT03878524 TERMINATED

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

NCT05107856 TERMINATED

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

Prelude Therapeutics

NCT03739554 COMPLETED

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

Cyclacel Pharmaceuticals, Inc.

NCT03833180 COMPLETED

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

NCT00697684 COMPLETED

Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant

Beth Israel Deaconess Medical Center

NCT01523223 COMPLETED

Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies

Robert Lowsky

NCT03624036 TERMINATED

Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Kite, A Gilead Company

NCT04978779 TERMINATED

A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Vincerx Pharma, Inc.

NCT04245722 TERMINATED

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Fate Therapeutics

NCT03884972 WITHDRAWN

Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor

M.D. Anderson Cancer Center

NCT03019055 COMPLETED

Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell

Medical College of Wisconsin

NCT05144347 TERMINATED

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

Exelixis

NCT01029366 COMPLETED

CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy

University of Pennsylvania

NCT05037669 WITHDRAWN

Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma

University of Pennsylvania

NCT01682616 COMPLETED

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

AbbVie

NCT02914938 TERMINATED

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

MEI Pharma, Inc.

NCT05176691 WITHDRAWN

HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

Hutchmed

NCT02890758 COMPLETED

Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803

Brenda Cooper, MD

NCT02960646 COMPLETED

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

M.D. Anderson Cancer Center

NCT03454165 COMPLETED

A Study of BNC105P Combined With Ibrutinib

Dartmouth-Hitchcock Medical Center

NCT02535286 COMPLETED

Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation

TG Therapeutics, Inc.

NCT01886859 COMPLETED

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

NCT02706392 TERMINATED

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

Fred Hutchinson Cancer Center

NCT03113695 COMPLETED

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

University of California, San Diego

NCT02529813 COMPLETED

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

M.D. Anderson Cancer Center

NCT01744912 TERMINATED

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

TG Therapeutics, Inc.

NCT01328626 COMPLETED

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

AbbVie

NCT04160195 TERMINATED

T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

National Cancer Institute (NCI)

NCT03639324 WITHDRAWN

Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL

Virginia Commonwealth University

NCT03263637 COMPLETED

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

AstraZeneca

NCT01353625 COMPLETED

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

Celgene

NCT00772486 COMPLETED

A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL

Memgen, LLC

NCT01767766 COMPLETED

Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

TG Therapeutics, Inc.

NCT01663766 TERMINATED

Phase I Study of Milatuzumab for Graft Versus Host Disease

Gilead Sciences

NCT01728207 TERMINATED

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL

Gilead Sciences

NCT01822509 COMPLETED

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

National Cancer Institute (NCI)

NCT03579888 TERMINATED

CD19-Specific T Cells Post AlloSCT

M.D. Anderson Cancer Center

NCT01644253 TERMINATED

Phase 1b Safety and Efficacy Study of TRU-016

Aptevo Therapeutics

NCT02669017 COMPLETED

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

ADC Therapeutics S.A.

NCT02129582 COMPLETED

Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies

Case Comprehensive Cancer Center

NCT02336048 TERMINATED

A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

Hoffmann-La Roche

NCT02242045 COMPLETED

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Gilead Sciences

NCT01088048 COMPLETED

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Gilead Sciences

NCT02948283 COMPLETED

Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia

City of Hope Medical Center

NCT03601819 TERMINATED

Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders

University of Michigan Rogel Cancer Center

NCT01300611 TERMINATED

TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation

Tarix Pharmaceuticals

NCT02900716 COMPLETED

Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas

Zhejiang DTRM Biopharma

NCT02538614 TERMINATED

Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia

Gilead Sciences

NCT02580552 COMPLETED

Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

miRagen Therapeutics, Inc.

NCT01671904 COMPLETED

A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Genentech, Inc.

NCT00674427 TERMINATED

Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant

University of Pennsylvania

NCT03807063 WITHDRAWN

Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

Fred Hutchinson Cancer Center

NCT02222688 COMPLETED

UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia

Thomas Kipps

NCT02316197 COMPLETED

Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia

Merck KGaA, Darmstadt, Germany

NCT02891590 COMPLETED

Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas

Zhejiang DTRM Biopharma

NCT04043845 WITHDRAWN

ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

Dana-Farber Cancer Institute

NCT02231853 TERMINATED

Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections

National Heart, Lung, and Blood Institute (NHLBI)

NCT01351935 COMPLETED

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Celgene

NCT02006485 COMPLETED

Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies

TG Therapeutics, Inc.

NCT01013441 COMPLETED

CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia

University of Pennsylvania

NCT02100852 COMPLETED

TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)

TG Therapeutics, Inc.

NCT02784834 TERMINATED

Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL

Michael Choi

NCT02614508 TERMINATED

Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Emory University

NCT01699152 COMPLETED

Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Tragara Pharmaceuticals, Inc.

NCT00880815 COMPLETED

Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

M.D. Anderson Cancer Center

NCT00697346 COMPLETED

Study of MLN8237 in Participants With Advanced Hematological Malignancies

Millennium Pharmaceuticals, Inc.

NCT02611908 WITHDRAWN

Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.

Michael Choi

NCT01634217 COMPLETED

Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation

Masonic Cancer Center, University of Minnesota

NCT02240719 COMPLETED

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

University of California, Davis

NCT01484015 COMPLETED

Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia

Wake Forest University Health Sciences

NCT02226861 COMPLETED

Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation

National Heart, Lung, and Blood Institute (NHLBI)

NCT02168907 TERMINATED

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Wake Forest University Health Sciences

NCT01129193 COMPLETED

AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

Amir Mortazavi

NCT01567709 COMPLETED

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

National Cancer Institute (NCI)

NCT01832922 COMPLETED

BR in Patients With CLL With Comorbidities and/or Renal Dysfunction

Dartmouth-Hitchcock Medical Center

NCT02137889 TERMINATED

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients

Novartis Pharmaceuticals

NCT01460134 COMPLETED

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Celldex Therapeutics

NCT01400685 COMPLETED

Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

Massachusetts General Hospital

NCT02200848 TERMINATED

Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Georgetown University

NCT00854646 COMPLETED

Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)

Traws Pharma, Inc.

NCT01534715 COMPLETED

IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

ImmunoGen, Inc.

NCT01121133 COMPLETED

A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax

AbbVie

NCT01110473 COMPLETED

ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies

AbbVie (prior sponsor, Abbott)

NCT01254578 COMPLETED

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

National Cancer Institute (NCI)

NCT01399840 COMPLETED

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Pfizer

NCT00614042 COMPLETED

Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma

Aptevo Therapeutics

NCT02381080 COMPLETED

Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

Janssen Research & Development, LLC

NCT01290549 COMPLETED

A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

Genentech, Inc.

NCT01610999 TERMINATED

Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation

Tufts Medical Center

NCT01300026 COMPLETED

AMG 319 Lymphoid Malignancy FIH

Amgen

NCT01209130 COMPLETED

A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma

Genentech, Inc.

NCT00714103 COMPLETED

8-Chloro-Adenosine in Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center

NCT01527838 COMPLETED

Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit

Fate Therapeutics

NCT02640833 WITHDRAWN

A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

AbbVie

NCT01871675 COMPLETED

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

SCRI Development Innovations, LLC

NCT01212380 COMPLETED

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)

Ohio State University Comprehensive Cancer Center

NCT01410513 COMPLETED

Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Sanofi

NCT01604031 TERMINATED

Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide

Baylor College of Medicine

NCT01076556 TERMINATED

Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

NCT01126502 TERMINATED

Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

National Cancer Institute (NCI)

NCT02258555 TERMINATED

Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma

Gilead Sciences

NCT02109224 TERMINATED

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

National Cancer Institute (NCI)

NCT01658319 COMPLETED

Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies

Case Comprehensive Cancer Center

NCT00608361 COMPLETED

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

National Cancer Institute (NCI)

NCT00963495 TERMINATED

Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy

University Health Network, Toronto

NCT00990587 COMPLETED

Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy

University Health Network, Toronto

NCT01149915 COMPLETED

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

Threshold Pharmaceuticals

NCT00735930 COMPLETED

Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

NCT00694590 COMPLETED

Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Genzyme, a Sanofi Company

NCT00864942 COMPLETED

Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

Georgetown University

NCT01120457 COMPLETED

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Bristol-Myers Squibb

NCT01650727 COMPLETED

A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)

Merck Sharp & Dohme LLC

NCT02117336 SUSPENDED

Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Piramal Enterprises Limited

NCT01005979 TERMINATED

A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)

Emory University

NCT01292135 COMPLETED

Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

Pharmacyclics LLC.

NCT01955668 COMPLETED

AZD6738 First Time in Patient Multiple Ascending Dose Study

AstraZeneca

NCT00828282 COMPLETED

High-dose HMG-CoA Inhibitor Simvastatin Relapsed CLL

John Haslip

NCT00933985 TERMINATED

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

National Cancer Institute (NCI)

NCT01231919 COMPLETED

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

National Cancer Institute (NCI)

NCT01161511 COMPLETED

Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia

Xencor, Inc.

NCT00890747 COMPLETED

Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

National Cancer Institute (NCI)

NCT01841489 COMPLETED

A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics

Gilead Sciences

NCT01251250 WITHDRAWN

Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia

Roswell Park Cancer Institute

NCT00612612 TERMINATED

Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

NCT01185262 COMPLETED

Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia

MD Anderson International Spain SA

NCT00947388 TERMINATED

Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

Case Comprehensive Cancer Center

NCT00749502 COMPLETED

A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)

Tesaro, Inc.

NCT00872976 WITHDRAWN

Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia

Bristol-Myers Squibb

NCT00807677 COMPLETED

A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Millennium Pharmaceuticals, Inc.

NCT00868413 COMPLETED

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

AbbVie (prior sponsor, Abbott)

NCT00593944 COMPLETED

Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)

Bristol-Myers Squibb

NCT00710528 COMPLETED

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

Gilead Sciences

NCT00800566 WITHDRAWN

Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)

M.D. Anderson Cancer Center

NCT01098188 COMPLETED

LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia

Laboratoire français de Fractionnement et de Biotechnologies

NCT01021358 COMPLETED

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).

Abbott

NCT00743028 COMPLETED

Assess the Oral Bioavailability of New ABT-263 Formulations

Abbott

NCT00730652 WITHDRAWN

Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma

Bristol-Myers Squibb

NCT00646165 TERMINATED

Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia

Mundipharma Research Limited

Full CLL Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only